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INTRODUCTION
Preeclampsia is a complication that occured in 3-7%
pregnancy and still one of maternal death major cause
(15-20% in developed countries) and perinatal death.1
The pathogenesis of preeclampsia is incompletely
known. Absent transformation or incomplete remod-
elling of spiral arteries due to incomplete trophoblast
invasion, was shown to occur during formation of the
placenta in preeclampsia and fetal growth retarda-
tion.1-3
Placental formation begins with trophoblast inva-
sion continued by spiral arteries remodelling. This
process involving extracellular matrix degradation
Abstract
Objective: To evaluate the effect of the  feeding of formula milk
enriched with pro-antioxidants to high sensitivity C-reactive protein
(hs-CRP) and cell-free mRNA of Plasminogen Activator Inhibitor-1
(PAI-1) in the first trimester, second trimester, and post labor for the
prevention of preeclampsia.
Method: This is double-blinded randomized clinical trial in 8-12
weeks pregnant woman with low (below 900 μmol/l) Ferric Reduc-
ing Ability of Plasma (FRAP), as a marker of low systemic antioxi-
dant. A total of 104 samples were collected from patients who had
antenatal care in Bunda Hospital Jakarta, Budi Kemuliaan Hospital,
and Dr.Cipto Mangunkusumo General Hospital from January 2007
until December 2009. From block randomization, 49 samples were
allocated in the case group, and 55 samples to the control group. A
formula milk enriched with pro-antioxidants was fed to the case
group throughout their pregnancy, and a regular pregnancy formula
milk was fed to the control group. Hs-CRP and cell-free mRNA
PAI-1 test in the two groups at first trimester, second, and post la-
bour was conducted. The incidence of preeclampsia was then com-
pared in the two groups.
Result: Significant difference (p<0.05) in preeclampsia rate, 1
sample (2%) in case group and 8 samples (14.5%) in control group
was found. Level of cell-free mRNA PAI-1 was significantly
(p<0.05) lower in the case group than in control group. Difference
of post labour cell-free mRNA PAI-1 level with first and second tri-
mester was lower in case group.
Conclusion: There was significant difference in preeclampsia
rate after subjects were fed with formula milk enriched by pro-anti-
oxidants. This difference was related with different mRNA PAI-1
which started in first trimester. Lower mRNA PAI-1 level in the
case group was found.
[Indones J Obstet Gynecol 2011; 35-4:179-85]
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Abstrak
Tujuan: Menilai pengaruh pemberian susu formula diperkaya
pro-antioksidan terhadap kadar plasma high sensitivity C-reactive
protein (hs-CRP) dan cell-free mRNA plasminogen activator inhibi-
tor-1 (PAI-1) pada trimester pertama, kedua dan pascapersalinan
sebagai usaha penurunan kejadian preeklampsia.
Metode: Merupakan uji klinis acak tersamar ganda pada wanita
hamil trimester pertama 8-12 minggu dengan Ferric Reducing Abil-
ity of Plasma (FRAP) yang rendah (di bawah 900 μmol/l), sebagai
petanda rendahnya antioksidan sistemik. Didapatkan 104 subjek
penelitian yang melakukan antenatal di RS Bunda Jakarta, RS Budi
Kemuliaan, dan Rumah Sakit Dr. Cipto Mangunkusumo pada perio-
de Januari 2007 sampai Desember 2009. Setelah dilakukan ran-
domisasi blok, didapatkan kelompok perlakuan 49 dan kontrol 55
orang. Kelompok perlakuan akan mendapat susu formula diperkaya
pro-antioksidan sepanjang kehamilan, sedangkan kelompok kontrol
mendapat susu hamil yang tersedia di pasaran. Kedua kelompok di-
lakukan pemeriksaan hs-CRP dan cell-free mRNA PAI-1 pada tri-
mester pertama, kedua dan pascapersalinan. Luaran utama yang di-
pantau adalah kejadian preeklampsia pada akhir kehamilan.
Hasil: Terdapat perbedaan kejadian preeklampsia yang ber-
makna (p<0,05) yaitu 1 orang (2%) pada perlakuan dan 8 (14,5%)
pada kelompok kontrol. Kadar hs-CRP plasma tidak didapatkan
perbedaan yang signifikan antar kelompok. Kadar cell-free mRNA
PAI-1 pada kelompok perlakuan secara signifikan lebih rendah
dibandingkan kontrol (p<0,05). Delta (selisih) cell-free mRNA PAI-
1 pascapersalinan dengan trimester pertama dan kedua lebih ren-
dah pada perlakuan.
Kesimpulan: Terdapat perbedaan bermakna kejadian preek-
lampsia pascapemberian susu formula diperkaya pro-antioksidan.
Perbedaan ini berhubungan dengan perbedaan kadar mRNA PAI-1
yang dimulai dari trimester pertama. Pada kelompok dengan pem-
berian susu diperkaya pro-antioksidan dibuktikan lebih rendah
kadar mRNA PAI-1.
[Maj Obstet Ginekol Indone s 2011; 35-4:179-85]
Kata kunci: preeklampsia, high sensitivity C-reactive protein
(hs-CRP), plasminogen activator inhibitor-1 (PAI-1)
Correspondence: Ridwan. Department of Obstetrics and Gynecology/Dr. Cipto Mangunkusumo Hospital, Jakarta.
Telephone: 021-99110205, Email: ridwanfkui2000@yahoo.com 
Vol 35, No 4 |
October 2011 Formula milk enriched with pro-antioxidants  179
|
which depends on proteolytic enzyme production,
such as plasmin that also has a function in fibrinolytic
process.2 Plasmin production is really dependant with
activator and inhibitor factors. Plasmin activator fac-
tor is tissue-type plasminogen activator (tPA) and
urokinase plasminogen activator (uPA). One of plas-
min inhibitor factor is Plasminogen activator inhibi-
tor-1.2,4
Plasminogen activator inhibitor-1 (PAI-1) which is
primarily produced by endothelial cell is a primary
plasminogen activator inhibitor to be a plasmin.5,6 In-
crease of PAI-1 in first trimester is suspected to alter
placentation process (trophoblast invasion, and spiral
arteries remodeling) and would lead to preeclampsia.2
Other mechanisms that were proved in preeclamp-
sia are endothelial dysfunction and increased maternal
inflammation response that occured in early preg-
nancy.1,3 This was proven by increase of endothelial
dysfunction and inflammation marker, especially C-
reactive protein (CRP), in the first and second trimes-
ter in preeclampsia.7 It was assumed that endothelial
dysfunction is because of inflammation process and
oxidative stress, and will also aggravate inflammation
and oxidative stress condition.8
C-reactive protein is an acute systemic inflamma-
tion marker, produced by liver and has important role
in immunology response.5,9-11
High sensitivity (hs) CRP is a CRP that measures
using enzyme (ELISA), fluorescence, and immunolu-
minometric. hs-CRP measurement is more sensitive
and better in showing systemic inflammation condi-
tion compare with conventional CRP measurement.9 
There were a lot of studies that tried to prove CRP
involvement as an inflammation marker and pree-
clampsia, but not all studies found the same result.
Kumru et al found that hs-CRP level in third trimester
preeclampsia patient was higher than in normal preg-
nancy and had a positive correlation with increase of
diastolic pressure in pregnant woman. Increased CRP
was not only because of systemic response inflamma-
tion in preeclampsia caused by endothelial dysfunc-
tion, but also because of higher placental apoptosis.
CRP had a role in increasing trophoblast cell phago-
cytosis.9 But Djurovic, et al found no relationship be-
tween inflammation and preeclampsia.12
In systemic endothelial dysfunction, like metabolic
syndrome and atherosclerosis, hs-CRP had a relation-
ship with PAI-1. Devaraj, et al also found that in-
crease of CRP also increased invitro production of
PAI-1.13
Increased production of PAI-1 was significantly
found in oxidative stress at endothelial cell in pree-
clampsia.4 Antioxidant treatment was proven to re-
duce PAI-1 production from atherosclerosis patient’s
endothelial cell.14
With involvement of oxidative stress as an impor-
tant pathogenesis of preeclampsia, it was suspected
that antioxidant suplement will reduce preeclampsia
rate. In 2006, Ruminis et al had proved it in Indone-
sia.15 But, the other studies found different result.1 
The objective of this study was to prove that the
feeding of formula milk enriched with pro-antioxi-
dants could decrease preeclampsia rate by decreasing
hs-CRP and cell-free mRNA PAI-1 mechanism start-
ing from early pregnancy.
mRNA PAI-1 test was conducted, not directly PAI-
1 protein. It was proven that mRNA being produced
represented systemic genomic signal with PAI-1 pro-
duction and had relationship with PAI-1 plasma
level.16
METHODS
This study was approved by University of Indonesia
Ethic Comission and all of the samples approved to
participate.
This was second grade clinical trial, phase III, dou-
ble blind-Randomized Clinical Trial.17
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Figure 1. Preeclampsia Pathogenesis1-2,7,10
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Samples were 8-12 weeks pregnant women who
had antenatal care in Bunda Hospital Jakarta, Budi
Kemuliaan Hospital, and Dr. Cipto Mangunkusumo
General Hospital from January 2007 until December
2009 with FRAP level below 900 μmol/l. Consecutive
sampling method was used, and 104 samples were
found.
Block randomization to determine case and control
group was used Case group was fed with formula
milk enriched with pro-antioxidants and control group
with usual milk for pregnant woman (prenagen®).
Samples were fed with milk throughout their preg-
nancy. The milk packaging and taste were disguised,
neither researchers nor patients knew.
Ingredients of formula milk feeding enriched by
pro-antioxidants were vitamin A 10,000 IU, vitamin
C 200 mg, vitamin E 400 IU, folic acid 400 μg, cal-
sium 800 mg, magnesium 100 mg, selenium 100 mg,
whey sistein protein 200 mg. Protein, fat and calori
component were same.
hs-CRP and cell-free mRNA PAI-1 test in the first
trimester (8-12 weeks), second trimester (20-24 weeks)
and 2 weeks postpartum was conducted. hs-CRP test
was done in Prodia laboratorium with immunolumi-
nometric method (IMMULITE® 2000). Cell-free
mRNA PAI-1 test was done in Showa University, To-
kyo, Japan. 5-7 cc blood samples were collected, cen-
trifuged 1600 G about 10 minutes in 4° C. Plasma
was deposited in – 20° C and posted to Japan cell-free
mRNA PAI-1 test with real-time quantitave reverse
transcription PCR was done Genom-equivalent was
used as quantity measurement.
Samples would be dropped out if they did not com-
plete the test.
Blood pressure, and anthropometric (body weight
and height) measurement was done.
The major outcome being evaluated was pree-
clampsia rate. The others were pregnancy age at birth,
and neonatal weight.
Definition of preeclampsia is hypertension in preg-
nancy (systolic pressure > 140 mmHg or diastolic >
90 mmHg) with two measurement in non dominant
upper arm while sitting, in more than 20 weeks preg-
nancy with proteinuria (> 300 mg/day).
Pregnancy age was measured by ultrasound in first
trimester. SPSS vs17 was used. If numeric data dis-
tribution was normal parametric (t-test) was used, if
it was not non-parametric (Mann-Whitney) was used.
Normal distribution data, was reported in mean +SD
form, abnormal one was in median (minimum-maxi-
mum) form. Kolmogorov-Smirnov test we used to de-
termine whether the numeric variable distribution was
normal or not. General Linear Model-Repeated Meas-
ured test was used in hs-CRP and cell-free mRNA
PAI-1 measurement serial.
RESULT
One hundred four samples who met the inclusion and
exclusion criteria were found. Case group were 49
samples and control group were 55 samples. The 104
samples, were being followed until labour. There
were 9 (8.6%) samples who became preeclampsia,
which consisted of 1 (2%) sample from case group
and 8 (14,5%) samples from control group (Table 1).
On socio-demografic data, there was no significant
difference in age category. There were 5 samples with
history of hypertension, 4 samples in control group,
1 sample in case group, but there was no significant
difference. Body Mass Index variable in first trimester
was higher in case group than in control group.
(Table 1.)
Table 1. Case and control group characteristics
Characteristics Control (n:55) Case (n:55) p
Age, years, mean+SD 29.7 ± 5.1 28.1 ± 5.1 0.77
Occupational status, n (%)
Working
Not working
30
25
21
28
0.16
Educational Status, n (%)
Low
Moderate
High
 3
24
28
 8
21
20
0.17
Smoking condition, n (%)
Active
Passive
Not smoking
14
 1
40
20
 1
28
0.55
History of Hypertension, n (%)
Yes
No
 4 (7.2) 
51 (92.7)
 1 (2.1) 
48 (97.9)
0.22
Body Mass Index, median (range)
First Trimester
Second Trimester
Third Trimester
22.1 (16.2–29.9)
24.1 (17.3–32.5)
26.7 (18.6–35.4)
23.3 (16.2–42.7)
25.1 (18.4–44.0)
26.7 (19.1–45.3)
0.04*
0.10
0.50
Neonatal birth weight, (gram) 3200 (1500–4000) 3126 ± 451 0.57
Pregnancy age at termination, (weeks) 39 (32–43) 39 (32–41) 0.26
*) significant difference with non-parametric (Mann-Whitney) testFigure 2. Research Algorithm
Vol 35, No 4 |
October 2011 Formula milk enriched with pro-antioxidants  181
|
 There was abnormal distribution data (hs-CRP and
cell-free mRNA PAI-1 plasma level) in whole sam-
ples. There was no significant difference in hs-CRP
level between the two groups (Table 2).
PAI-1 level in case groups were lower than in con-
trol group, starting from first, second trimester, until
postpartum (Table 3).
mRNA PAI-1 deviation in first-second trimester
were not significantly different. Postpartum-first trimes-
ter deviation and postpartum-second trimester devia-
tion was significantly different in case and control
group (p<0.05).
Table 2. Preeclampsia outcome in each group
Preeclampsia rate Control (n:55) Case (n:49) p RRR
No preeclampsia, n(%) 47 (84.5) 48 (98) 0.03* 62.5%
Preeclampsia, n(%)  8 (14.5)  1 ( 2)
* Fisher test
Table 3. hs-CRP distribution in case and control group
hs-CRP (mg/l) Control (n:55)median (range)
Case (n:55)
median (range) p*
First Trimester 3.10 (02–102) 3.98 (0.32–21) 0.66
Second Trimester 3.97 (0.42–27.48) 4.07 (0.54–72.2) 0.88
Post Partum 5.52 (0.28–89.0 ) 7.47 (0.33–72.2) 0.52
*non-parametric (Mann-Whitney) test
In the calculation of the General Linear Model
(GLM) of repeated measurement was found signifi-
cant differences in the increment of PAI-1 mRNA be-
tween the control and the case group (p=0.02) as in
the chart above.
If both groups are combined and are performed
comparative evaluation of subjects who became pree-
clamsia (Table 5), then will be found that hs-CRP
levels are higher in preeclampsia, both the first tri-
mester, second trimester and postpartum, but the sta-
tistics will not be significant.
Table 5. The distribution of hs-CRP in normal pregnancy and
preeclampsia subjects
hs-CRP (mg/l) Normal pregnancy (n:95)median (range)
Preeclampsia (n:9)
median (range) p
First Trimester 3.1  (0.2–30.33)  6.34 (1.27–102) 0,056
Second Trimester 3.83 (0.42–72.2)  7.87 (1.31–14.7) 0,053
Post Partum 5.85 (0.28–78.4) 13.4  (1.26–89  ) 0,91
Mann-Whitney test
DISCUSSION
In this study, it was found that the incidence of pree-
clampsia in population study was 8.6%, not much dif-
ferent from the incidence in the general population.1,3
Sociodemographic data in both groups of research
subjects only different on variable of Body Mass In-
dex (BMI) in first trimester, while the variables of
age, history of hypertension, and smoking habits did
not have differences.
This is important to analyze, considering pre-
eclampsia was already proven to have a strong risk
factor, especially a history of hypertension or pre-
vious preeclampsia and obesity.1 In the case of it is
obesity, often associated with increased systemic in-
flammation and insulin resistance that would increase
preeclampsia.1,18
The habit of smoking had an inverse relationship
with preeclampsia because it demonstrated a lower
incidence of preeclampsia in pregnant women smok-
ers. This is presumable related to the role of nicotine
as a trigger to the release of nitric oxide by a receptor
in the placenta and as reducer of free radical produc-
tion.19 The initial data before the treatment was
proven to be equivalent in the control and case group.
Previous history of hypertension or preeclampsia
should also be made equivalent to reduce confounding
factors.1
The interesting thing in this study was Body Mass
Index (BMI) variable was higher at baseline in the
treated group than in, the control group, but had lower
rates of preeclampsia. This gave an idea/opportunity
that the administration of pro-antioxidant-enriched
milk may reduce the incidence of preeclampsia, al-
though in cases of excess weight. Of course this
should be proved by a sharper research.1,18,20-21
Table 4. Distribution of PAI-1 in the control and case group
PAI-1
(genom-Equivalent)
Control (n:55)
median (range)
Case (n:55)
median (range)
p
First Trimester  251.63 (206.52–397.49)  238.56 (203.82–320.15) 0,016*
Second Trimester  506.64 (413.04–794.98)  477.19 (407.64–640.29) 0,007*
Post Partum  2026.57 (1264.63–3179.91) 1908.79 (1630.57–2561.18) 0,005*
Δ2nd Trimester - 1st Trimester  255.78 (21.69–518.67)  229.85 (153.38–412.99) 0,09
ΔPost Partum- 1st Trimester  1777.98 (1056.56–2934.15) 1660.24 (1387.05–2319.81) 0,01*
ΔPost Partum- 2nd Trimester 1548.47 (713.35–2686.38) 1404.82 (1059.80–2094.39) 0,04*
*Nonparametric test (Mann-Whitney)
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Outcomes of neonatal birth weight and gestational
age did not differ between control and case groups.
After being evaluated, the reason was because of its
relatively small numbers of subjects, especially the
numbers of preeclampsia in the treated group, only 1
subject. With the pathogenesis of preeclampsia which
primarily involves the process of placentation, then
the possibility of stunted fetal growth and preterm
births will increase.1,5
The pro-antioxidant-enriched formula feeding in
this study gave evidence that it could reduce the in-
cidence of preeclampsia from 14.5% to 2%. This is
relevant with Rumiris et al study.15
Parameters in clinical trial that can also be assessed
is the experimental event rate (EER) or the proportion
of milk failure in preventing preeclampsia in case
group which was 2%. While the control event rate
(CER) or the failure of milk in preventing preeclamp-
sia in control group was 14.5%.
Relative risk reduction (RRR) in this study was
about 62.5%, meaning that the provision of infant for-
mula enriched with pro-antioxidants decreased the
rate of preeclampsia about 62.5% in pregnant women
with low antioxidant.
Absolute risk reduction (ARR) or the incidence of
factual preeclampsia between the control and case
group was 12.5%.
Number needed to treat (NNT) or number of sub-
jects that should be given milk to prevent one inci-
dence of preeclampsia in this study were 8 pregnant
women with low levels of antioxidants.
The mechanisms that underline the work of anti-
oxidant administration in reducing the incidence of
preeclampsia is not fully understood. One of which
presumably is the improvement of systemic oxidative
stress that occurs. These conditions of oxidative stress
triggers inflammation and endothelial dysfunction, in-
cluding platelet aggregation.1
In this study, the obtained hs-CRP plasma levels
of both groups were not significant. This does not
support the theory that linked the involvement of the
inflammatory process that occurs with oxidative stress
in preeclampsia.5,7,10
However, if the calculated statistics in both groups
were combined and the variable hs-CRP was com-
pared, it is clear that hs-CRP in subjects who suffer
from preeclampsia is higher than in normal ended
pregnancy, although the statistics was not significant.
This is because the number of samples is less to com-
pare the preeclampsia group (only 9 subjects from 104
subjects) with normal pregnancies.
Several clinical explanation on why the two
groups, either treated or control were not different in
levels of CRP is because the mechanism of hs-CRP
production is heavily influenced by other inflamma-
tory factors. On the subjects were made an exclusion
of other infection such as respiratory tract infections,
urinary tract infections and so on throughout the preg-
nancy.22
The interesting thing from this study was the ten-
dency of hs-CRP to increase in the second trimester
and postpartum compared to the first trimester. This
explanation was proposed by Sibai et al, that preg-
nancy itself is an inflammatory condition, especially
in third trimester.1 So it can be said that this study
also supports this theory. Preeclampsia happens in a
severe/extreme systemic inflammatory conditions
such that systemic endothelial damage will occur.1
The maternal systemic inflammation relation to the
pathogenesis of preeclampsia has been widely studied
several decades.11 The explanation that can be ad-
duced is debris of placental trophoblast escape into
the maternal circulation.23 Trophoblast debris is nor-
mally found in small amounts in the blood of pregnant
women. In conditions of impared trophoblast invasion
and increased oxidative stress, especially in pre-
eclampsia, trophoblast apoptosis occurs much so that
the amount of the released trophoblast into the ma-
ternal circulation is increased.24 This trophoblast is
semiallogenic (partly derived from the genetic pater-
nal), would trigger maternal systemic inflammatory
reactions.25 Inflammatory mediators that are released
will further increase trophoblast apoptosis so it will
multiply trophoblast escape into the circulation, like
a vicious circle.26 Moreover, the process of oxidative
stress in preeclampsia that occurs also triggers a sys-
temic inflammatory process.27 However, this study
did not support the above theory.
This study found that the factor proven to be as-
sociated with the incidence of preeclampsia is cell-
free mRNA PAI-1. This is similar to the results of
Purwosunu et al study.2 The control group, had sig-
nificantly greater mRNA expression of PAI-1
genomic than the case group since the first trimester
of pregnancy. The difference is consistent with the
pathogenesis previously thought, namely the role of
PAI-1 as a primary inhibitor of plasmin enzymes
work in protein degradation in the process of remo-
delling the decidual spiralis arteries.2
This study also supports the theory which state
that preeclampsia process has been started since the
beginning of pregnancy (first trimester). Farina et al
also showed that preeclampsia can be predicted at the
age of 10-14 weeks, by examining specific angiogene-
sis factor mRNAs.28
The production of PAI-1 mPRNA was also found
growing in the second trimester and postpartum when
compared with the first trimester, either in treatment
or control group. Explanation that could be found is
physiological hypercoagulable state in pregnancy. The
production of plasmin itself was also increased in hy-
percoagulable state of pregnancy. In the control group
with higher PAI-1 in the second trimester and post-
partum, preeclampsia were found many instances. The
relationship of this event with preeclampsia is a pos-
sibility of spiral arteries and thrombosis leading to
infarction of the placenta that have been proved partly
occur in preeclampsia.29 Spiral arteries thrombosis
was also proven to be closely associated with endo-
thelial dysfunction caused by increased oxidative
stress in preeclampsia.30 Endothelial dysfunction that
occured resulting in increased endothelial cells per-
meability and platelet aggregation. Incidence of plate-
let aggregation is considered hypercoagulable and
causing thrombosis.30
Another investigation in this study was the role of
infant formula enriched with pro-antioxidants on the
production of PAI-1. In this study, pro-antioxidant
fortified milk to suppress the production of cell-free
mRNA PAI-1 which is a genomic signal for the pro-
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duction of PAI-1. This was proven by the difference
in PAI-1 in second trimester-first trimester, postpar-
tum-first trimester, as well as postpartum-second tri-
mester between groups (Table 4), although there was
significant statistical difference in postpartum-first tri-
mester and postpartum-second trimester (p<0.05).
The mechanism of suppresion of mRNA produc-
tion of PAI-1 done by the feeding of formula enriched
with pro-antioxidant is assumed to suppress oxidative
stress conditions27 as a part of the pathogenesis of
preeclampsia. The production of PAI-1 alone increased
in systemic oxidative stress studied by Oszajca et al4
and Furumaya et al.31
In this study, the differences in PAI-1 mRNA were
also obtained to be different in the second trimester
and postpartum between the control and case group.
These results support several previous studies, espe-
cially Purwosunu et al. at the third trimester.2 Mecha-
nisms that could explain the release of placental
mRNA into the maternal circulation in preeclampsia
due to infarction of the placenta.2 Trophoblast itself
is still there in the placental bed spiral arteries until
the puerperium completed, and suffered massive
apoptosis. Purwosunu et al in another study was also
to prove the same thing as postpartum, although only
a portion of the mRNA of angiogenesis factors, not
the PAI-1.32
From this study it can be concluded that feeding
of formula milk enriched with pro-antioxidants can
significantly decrease the incidence of preeclampsia
in pregnant women with conditions of lower systemic
antioxidant (FRAP < 900 μmol/l).
One of the pathophysiology as proven by this study
is the role of PAI-1 produced by endothelial started
in the first trimester where the implantation of tro-
phoblast process and spiral artery remodeling begins.
The feeding of formula milk enriched with pro-anti-
oxidants can suppress the production of PAI-1
genomic mRNA so that the function of plasmin en-
zyme in the process of remodeling the spiral arteries
will get better and in the second trimester the produc-
tion of PAI-1 mRNA is suppressed, so that the inci-
dence of platelet aggregation is decreased.
The role of inflammation as the pathogenesis of
preeclampsia, characterized by hs-CRP, in this study
there was an increasing trend, but it needs more sub-
jects.
The advantages of this research are the increasing
of complex pathogenesis of preeclampsia through the
inflammation and the involvement of PAI-1 and the
relating to oxidative stress as well as direct clinical
interventions such as pro-antioxidant fortified milk
that can be applied in the management of patients for
prevention.
Limitations of this study was not examined other
factors involved in the pathogenesis of preeclampsia
as a complex of other oxidative stress enzymes such
as Superoxide Dimutase (SOD), glutathione peroxi-
dase (GPX), as well as the factors pro and anti-angio-
genesis. The involvement of PAI-1 is only one part
of the pathogenesis of preeclampsia. It required a
more complex study, but certainly with larger subjects
of research and fund.
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